Retatrutide vs tirzepatide vs semaglutide: trials and evidence, 2026
Semaglutide, tirzepatide and retatrutide are different molecules. Semaglutide targets GLP-1, tirzepatide targets GIP and GLP-1, and retatrutide is studied as a GIP, GLP-1 and glucagon receptor agonist. More receptor targets does not automatically mean greater safety or a better treatment for an individual.
Published trial results through October 21, 2026
These are outcomes from defined clinical-trial medicines, not tests of Locked Aminos materials. Negative percentages mean weight reduction from baseline. Sample sizes are whole-trial randomized counts, not a single arm. The rows deliberately show comparator, follow-up and estimand instead of presenting a winner.
| Study / publication | Model, population and follow-up | Reported weight endpoint / estimand | Safety and interpretation limits |
|---|---|---|---|
| STEP-1 · Semaglutide · 2021 | 1,961 adults without diabetes; randomized placebo-controlled; 68 weeks | Mean weight change −14.9% versus −2.4% placebo; treatment-policy estimand, including discontinuation/rescue events. | Gastrointestinal events and related discontinuations occurred; trial population, product and follow-up limit transferability. |
| SURMOUNT-1 · Tirzepatide · 2022 | 2,539 adults without diabetes; randomized placebo-controlled; 72 weeks | Highest-dose study group: −20.9% versus −3.1% placebo; treatment-regimen estimand. | Gastrointestinal events were common; this is not a direct comparison with STEP-1 or a result for a research vial. |
| Retatrutide · Phase 2 · 2023 | 338 adults; randomized placebo-controlled; 48-week result | Highest-dose study group: −24.2% versus −2.1% placebo in the published efficacy analysis. | Small dose-finding trial; gastrointestinal effects and heart-rate changes reported. Different estimand and duration from the other rows. |
| SURMOUNT-5 · Direct comparison · 2025 | 751 adults with obesity without diabetes; randomized, open-label; 72 weeks | Tirzepatide −20.2% versus semaglutide −13.7%; maximum tolerated study regimens. | A genuine head-to-head trial, but open-label and without retatrutide. Does not establish individual suitability or rank all three molecules. |
| TRIUMPH-1 · Retatrutide Phase 3 · 2026 | 2,339 adults with obesity without diabetes; randomized double-blind; 80 weeks | Published treatment-regimen/ITT weight changes: −17.6%, −23.7%, −25.0% across study groups versus −3.9% placebo. | Gastrointestinal events most common. Not a comparison with tirzepatide or semaglutide; the company’s efficacy-estimand headline is a different analysis. |
| TRIUMPH-2 · Retatrutide Phase 3 · 2026 | 1,152 adults with obesity/overweight AND type 2 diabetes; randomized double-blind; 80 weeks | Treatment-regimen weight changes: −11.9%, −16.8%, −18.8% across study groups versus −5.1% placebo. | Different population from TRIUMPH-1. Gastrointestinal events, hypotension and altered sensation were more frequent with retatrutide; discontinuations matter. |
Why a 28.3% headline and a 25.0% result can coexist
Lilly’s May 21, 2026 TRIUMPH-1 release reported 28.3% in the highest-dose group under an efficacy estimand. The September 29 peer-reviewed paper reports 25.0% for that group under its treatment-regimen/ITT weight analysis. These answer different questions about treatment discontinuation and other intercurrent events. They are not interchangeable and neither establishes superiority over another drug from a different trial.
Retatrutide remained investigational in the current developer material checked for this update. TRIUMPH-5 (NCT06662383) is the registered retatrutide–tirzepatide comparison: active, not recruiting, with no posted results on October 21, 2026; record last posted July 20, 2026. Estimated completion dates are plans, not findings. Authorization for semaglutide or tirzepatide belongs to a specific medicine and indication; check Israel’s actual medicine record, not a research-material listing.
How this comparison will be maintained
The source record stores trial ID, registry ID and publication date separately. Review new peer-reviewed reports, registry changes and developer status at least monthly and when major results appear; this is an editorial requirement, not a claim of automatic trial surveillance. Preserve prior estimand labels and a dated change note. Do not replace a trial result with an unsourced promotional headline.
Primary sources and verification records
- STEP-1 · published 2021-02-10
- SURMOUNT-1 · published 2022-06-04
- Retatrutide phase 2 · published 2023-06-26
- SURMOUNT-5 · published 2025-05-11
- TRIUMPH-1 · published 2026-09-29
- TRIUMPH-2 · published 2026-09-29
- Lilly May 21, 2026: developer announcement, efficacy estimand
- Lilly September 29, 2026: current investigational status
- TRIUMPH-5 registry, checked October 21, 2026
- Israel Ministry of Health: medicine database

Mechanism is only the first comparison
A receptor profile describes part of a molecule’s pharmacology. It does not summarize dose exposure, tolerability, long-term outcomes or the manufacturing quality of a supplied product. Catalog abbreviations such as GLP-1, GLP-2 and GLP-3 are not a scientific ranking system; use the full compound identities.
Why trial percentages are not a league table
Different trials may enroll different populations, use different comparators and follow participants for different durations. Outcomes may use different estimands or handle missing data differently. Comparing headline percentages across those studies is not the same as a randomized head-to-head comparison. Read the methods and uncertainty before drawing a conclusion.
Medicine authorization belongs to a particular product
An authorization concerns a defined medicine, manufacturer, presentation and indication. It cannot be transferred to a separate research vial with the same active-ingredient name. Check the actual Israeli medicine record and professional guidance. Retatrutide remains described as investigational in the developer communication cited in our research guide.
A better evidence note
For each paper, record the molecule, study product, phase, population, comparator, follow-up, primary outcome and reported safety limits. Keep a separate note for the identity and batch quality of any laboratory material. This two-record approach prevents a clinical result from being mistaken for a certificate for a catalog item.
Sources and review scope
Sources explain terminology and evidence limits. They are not commercial endorsements or approvals of catalog products. Check the original source for updates.
Catalog identity and documentation
These links identify laboratory materials, not treatments or clinical-trial products.
